?Product Name?: tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate (Edoxaban Intermediate)
?CAS No.?: 365998-36-3

?? ?Product Overview?
A high-purity pharmaceutical intermediate critical for synthesizing ?Edoxaban? (CAS 480449-70-5), a leading ?direct oral anticoagulant (DOAC)? used to prevent stroke and systemic embolism in patients with atrial fibrillation. With ?≥98% purity? (HPLC-certified), it ensures precision in API manufacturing and R&D for next-generation thrombin inhibitors. Available in bulk quantities (1kg–25kg) with industrial-grade packaging options.

?? ?Key Advantages?
? ?High Purity?: ≥98% (up to 99% by HPLC/GC), minimizing impurities in API synthesis.
?? ?Scalable Supply?: Customizable packaging (1kg, 5kg, 25kg) for lab and industrial use.
?? ?Batch Traceability?: COA provided for compliance with pharmaceutical standards.

?? ?Applications?

1. ?Anticoagulant Production?: Core intermediate for Edoxaban API synthesis.

2. ?R&D of Thrombin Inhibitors?: Supports development of novel cardiovascular drugs.

3. ?Global Export?: Widely used in pharmaceutical and chemical reagent markets.

?? ?Quality Certification?

• ?Testing Standards?: HPLC, GC, NMR, and mass spectrometry.

• ?Compliance?: Meets ISO 9001 and ICH Q7 guidelines for intermediates.

?? ?Market Trends?
Demand for Edoxaban intermediates is rising due to ?patent expirations (2024–2026)? and increasing global prevalence of cardiovascular diseases. The DOAC market is projected to grow at ?8.4% CAGR (2025–2030)?, driven by aging populations and demand for cost-effective generics. Asia-Pacific dominates API production, with suppliers offering ?GMP-ready batches? gaining market share.